Euronext: Unsurprisingly strong quarter. Fagron: Somewhat softer 1Q26 expected, FY guidance maintained. Randstad: Preview 1Q26F results due 22 April; consensus released. Staffing: French staffing: February touch softer but March outlook better. Theon International: Teaming up with Rheinmetall
Fagron reported 1Q26 revenues 1% above CSS expectations. Organic revenue growth of 3.2% at CER was supported by all regions, driven in particular by DD growth in Latin America. Despite losing the GLP-1 tailwind, North America still delivered positive organic growth. The continued focus on Brands is clearly paying off, with 22.6% organic revenue growth at CER y/y. Acquisition integrations are progressing as planned. FY26 guidance for MDS to HSD organic revenue growth at CER is reiterated, Fagron ...
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER1), supported by incremental M&A contribution and outstanding performance in Latin AmericaOr...
Fagron rapporteert in het eerste kwartaal een solide omzet van € 263 miljoen, met een omzetgroei van 10% Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 9 april 2026 – 7:00 uur CET Fagron rapporteert in het eerste kwartaal een solide omzet van € 263 miljoen, met een omzetgroei van 10% Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar kwartaalresultaten voor de periode eindigend op 31 maart 2026. Belangrijkste hoogtepunten Omzet van € 263,4 miljoen, een stijging van 10,3% op basis van gerapporteerde cijfers (15,0% tege...
We update our estimates with our c.6% higher Adj. EBITDA estimates for 2026F-28F largely driven by recent M&A's. We expect Fagron's trading update on 9 April to point to a somewhat softer quarter, reflecting temporary headwinds in the North American compounding segment. However, Fagron should reiterate its FY26 guidance of mid- to high-single digit organic revenue growth as growth should spring back in 2H26 as GLP1 headwinds fade. We reiterate our BUY recommendation and €27 per share target pric...
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
Fagron increases share capital through exercise subscription rights Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84. The total number of shares with voting rights after the issue amounts to 73,773,104 which is also ...
Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 31 maart 2026 – 19:00u. CET Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Fagron maakt bekend dat er op 31 maart 2026 104.200 nieuwe aandelen zijn uitgegeven als gevolg van de uitoefening van inschrijvingsrechten. Overeenkomstig de Belgische transparantiewetgeving deelt Fagron mee dat haar maatschappelijk kapitaal na de uitgifte € 507.462.601,84 bedraagt. Het totaal aantal stemrechtverlenende effecten na de uitgifte bedraagt 73.773.1...
Disclosure of a transparency notification from Aberdeen Group plc Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 March 2026. Notification from Aberdeen Group plc On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company that its shareholding has...
Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 20 maart 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, gedateerd op 16 maart 2026. Kennisgeving van Aberdeen Group plc Op 19 maart 2026 ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, waarin aan...
Our analysis of U.S. compounding capacity and utilization shows that North America can sustain double-digit organic growth, driving our 7.4% organic revenue CAGR (25–30) for the group. We expect strong REBITDA growth in 2026, and margin decrease due to acquisitions. Long-term margin upside is well supported by the new U.S. facilities and improved efficiency through centralized manufacturing and vertical integration in LatAm. The market continues to undervalue Fagron by focusing too heavily on ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.